Literature DB >> 29939858

Paroxysmal Sympathetic Hyperactivity and Clinical Considerations for Patients With Acquired Brain Injuries: A Narrative Review.

Alphonsa Thomas1, Brian D Greenwald.   

Abstract

The term "storming" has often been used colloquially to characterize patients with brain injury who showed signs and symptoms of elevated heart rate, blood pressure, respiratory rate, temperature, and motor posturing. Recently, the term paroxysmal sympathetic hyperactivity has been used as the unifying term to describe these acute episodes of elevated sympathetic hyperactivity. Various pharmaceutical and management options are available, but no single drug or protocol has been deemed superior to the others. Data on prognosis and recovery in relation to paroxysmal sympathetic hyperactivity are limited but point toward poorer functional outcome and increased mortality. Overall, the phenomenon of paroxysmal sympathetic hyperactivity requires further research to aid rehabilitative efforts so that patients can effectively participate in therapy. A review of the literature has revealed sparse information on the management of sympathetic storming within rehabilitation facilities. This narrative review seeks to provide an up-to-date synopsis and recommendations on the management of rehabilitation inpatients with paroxysmal sympathetic hyperactivity.

Entities:  

Mesh:

Year:  2019        PMID: 29939858     DOI: 10.1097/PHM.0000000000000990

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  2 in total

Review 1.  Identification and Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury.

Authors:  Rui-Zhe Zheng; Zhong-Qi Lei; Run-Ze Yang; Guo-Hui Huang; Guang-Ming Zhang
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

Review 2.  Paroxysmal Sympathetic Hyperactivity in Moderate-to-Severe Traumatic Brain Injury and the Role of Beta-Blockers: A Scoping Review.

Authors:  Stéphane Nguembu; Marco Meloni; Geneviève Endalle; Hugues Dokponou; Olaoluwa Ezekiel Dada; Wah Praise Senyuy; Ulrick Sidney Kanmounye
Journal:  Emerg Med Int       Date:  2021-09-11       Impact factor: 1.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.